Trials / Completed

CompletedNCT05363670

Administration of ARS-1 or Albuterol in Subjects With Persistent Asthma

A Phase 2, Single-Dose, Randomized, Active and Placebo Controlled, Four-Period, Cross-Over Study of the Safety and Efficacy of Intranasal Epinephrine After Administration of ARS -1 or Albuterol in Subjects With Persistent Asthma

Status: Completed
Phase: Phase 2
Study type: Interventional
Enrollment: 18 (actual)

Sponsor: ARS Pharmaceuticals, Inc. · Industry
Sex: All
Age: 12 Years – 65 Years
Healthy volunteers: Not accepted

Summary

ARS-1 is being developed for patients as a needleless alternative route of epinephrine administration for the management of refractory asthma symptoms.

Conditions

Asthma

Interventions

Type	Name	Description
DRUG	ARS-1	ARS-1
DRUG	Albuterol MDI	180 mcg
DRUG	Placebo	Placebo

Timeline

Start date: 2022-07-28
Primary completion: 2024-02-02
Completion: 2024-02-02
First posted: 2022-05-06
Last updated: 2024-07-30

Locations

4 sites across 1 country: United States

Regulatory

FDA-regulated drug study

Source: ClinicalTrials.gov record NCT05363670. Inclusion in this directory is not an endorsement.